Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$4.66 USD
-0.34 (-6.80%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $3.78 -0.88 (-18.88%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
PBYI 4.66 -0.34(-6.80%)
Will PBYI be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PBYI
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Other News for PBYI
Puma Biotechnology dips after dismissal of its suit was granted by a federal judge
Buy Rating on Puma Biotechnology Amid Financial Challenges and Drug Advancement Prospects
Puma Biotechnology price target lowered by $1 at H.C. Wainwright, here's why
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Puma Biotechnology (PBYI) and MoonLake Immunotherapeutics (MLTX)
Puma Biotech: Q4 Earnings Snapshot